



Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal *Prevotella* spp., promote Toll-like receptor 2-independent lung inflammation and pathology

Larsen, Jeppe Madura; Musavian, Hanieh Sadat; Butt, Tariq Mahmood; Ingvorsen, Camilla; Thysen, Anna Hammerich; Brix, Susanne

Published in:
Immunology

Link to article, DOI:
[10.1111/imm.12376](https://doi.org/10.1111/imm.12376)

Publication date:
2015

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):

Larsen, J. M., Musavian, H. S., Butt, T. M., Ingvorsen, C., Thysen, A. H., & Brix, S. (2015). Chronic obstructive pulmonary disease and asthma-associated Proteobacteria, but not commensal *Prevotella* spp., promote Toll-like receptor 2-independent lung inflammation and pathology. *Immunology*, *144*(2), 333-342.
<https://doi.org/10.1111/imm.12376>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **COPD and asthma-associated Proteobacteria, but not commensal Prevotella spp.,**
2 **promote TLR2-independent lung inflammation and pathology**

3
4
5
6 Jeppe Madura Larsen, PhD, Hanieh Sadat Musavian, MSc, Tariq Mahmood Butt, MSc,
7 Camilla Ingvorsen, PhD, Anna Hammerich Thysen, PhD and Susanne Brix, PhD

8
9
10 Systems Biology of Immune Regulation, Center for Biological Sequence Analysis, Department of Systems
11 Biology, Technical University of Denmark, Lyngby, Denmark

12
13
14
15 Running title: Lung inflammation in response to common airway bacteria

16
17
18
19 Corresponding author: Jeppe Madura Larsen, Systems Biology of Immune Regulation, Center for Biological
20 Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Søltofts Plads 224,
21 2800 Lyngby, Denmark. E-mail: jeml@bio.dtu.dk

1 **Abstract**

2 Recent studies of healthy human airways have revealed colonization by a distinct commensal bacterial
3 microbiota containing Gram-negative *Prevotella* spp. However, the immunological properties of these
4 bacteria in the respiratory system remain unknown. Here we compare the innate respiratory immune
5 response to three Gram-negative commensal *Prevotella* strains (*Prevotella melaninogenica*, *Prevotella*
6 *nanceiensis* and *Prevotella salivae*) and three Gram-negative pathogenic Proteobacteria known to colonize
7 lungs of COPD and asthma patients (*Haemophilus influenzae* B, non-typeable *Haemophilus influenzae* and
8 *Moraxella catarrhalis*). The commensal *Prevotella* spp. and pathogenic Proteobacteria were found to
9 exhibit intrinsic differences in innate inflammatory capacities on murine lung cells *in vitro*. *In vivo* in mice,
10 non-typeable *Haemophilus influenzae* induced severe TLR2-independent COPD-like inflammation
11 characterized by predominant airway neutrophilia, expression of a neutrophilic cytokine/chemokine profile
12 in lung tissue, and lung immunopathology. In comparison, *Prevotella nanceiensis* induced a diminished
13 neutrophilic airway inflammation and no detectable lung pathology. Interestingly, the inflammatory airway
14 response to the Gram-negative bacteria *Prevotella nanceiensis* was completely TLR2-dependent. These
15 findings demonstrate weak inflammatory properties of Gram-negative airway commensal *Prevotella* spp.
16 that may make colonization by these bacteria tolerable by the respiratory immune system.

1 **Keywords**

2 Respiratory inflammation; commensal microbiota; *Prevotella*; Proteobacteria; COPD; asthma; lung
3 immunopathology.

4

5 **Abbreviations**

6 BAL: Bronchoalveolar lavage; DC: Dendritic cell; HE: hematoxylin-eosin; H. inf. B: *Haemophilus*
7 *influenzae* B; H. inf. NT: non-typeable *Haemophilus influenzae*; LPS: Lipopolysaccharide; M. cat.: *Moraxella*
8 *catarrhalis*; MAMP: Microbial-associated molecular pattern; P. mel.: *Prevotella melaninogenica*; P. nan.:
9 *Prevotella nanceiensis*; P. sal.: *Prevotella salivae*; TLR: Toll-like receptor; WT: Wild-type.

10

11

12

13

1 Introduction

2 The role of commensal bacteria in health and disease is receiving increasing interest with the
3 recognition that the microbiota plays a central role in shaping immune function, metabolism and protection
4 from pathogenic microorganisms (1–3). The human lung has historically been considered sterile due to the
5 absence of cultivable bacteria in bronchial alveolar lavage fluids from healthy individuals (4–6). However,
6 culture-independent molecular methods for bacterial identification have recently been applied to
7 characterize the human airway microbiota (7–11). Gram-negative anaerobic *Prevotella* species were found
8 to be a prevalent bacterial colonizer of healthy airways (7, 11), and reduced frequencies were reported in
9 chronic obstructive pulmonary disease (COPD) and asthma (7). *Prevotella* species are considered
10 commensal bacteria that rarely cause respiratory infections, and only few strains have been reported to be
11 opportunistic in chronic infections, abscesses and anaerobic pneumonia (12–14).

12 Dysbiosis, a change in microbiota composition detrimental for host health, is associated with altered
13 function of the immune system and inflammatory pathologies (15). It is becoming increasingly appreciated
14 that respiratory bacterial pathogens commonly colonize the lower airways of patients with COPD and
15 asthma (7, 16, 17). Both stable disease and exacerbation episodes in COPD are predominantly associated
16 with the presence of pathogenic Gram-negative Proteobacteria (*Haemophilus influenzae* and *Moraxella*
17 *catarrhalis*) (18–20). The pathogenic Proteobacteria are believed to take part in disease progression of
18 COPD by enhancing inflammatory processes and tissue degradation in the lower airways (21). Indeed,
19 higher bacterial loads in the airways are associated with increased disease severity, exacerbation
20 frequency, decreased lung function and increased production of inflammatory mediators (22–24). The
21 notion of disease-promoting properties of bacteria is further supported by a recent interventional study
22 showing that prophylactic antibiotic treatment reduced the frequency of bacterial colonization and
23 exacerbations in COPD (25).

24 A role for pathogenic Proteobacteria in asthma pathology remains controversial and few studies are
25 found in the literature. Increased airway colonization by pathogenic Proteobacteria is associated with

1 stable asthma in children and adults (7), exacerbation episodes in childhood (26) and increased risk of
2 developing asthma (17). We recently reported abnormal bacterial immune responses in infants later
3 developing asthma proposing that asthmatics exhibit decreased bacterial control and that divergent
4 bacterial immune responses within the lung may contribute to asthma pathology in some disease
5 endotypes (27).

6 Studies using murine models of COPD demonstrated that *Haemophilus influenzae* enhances airway
7 inflammation induced by cigarette smoke exposure (28, 29). Furthermore, mice challenged in the airways
8 with *Haemophilus influenzae* lysates develop inflammatory features of COPD, including production of pro-
9 inflammatory mediators TNF α , IL-6 and IL-1 β , airway neutrophilia and lung tissue pathology (30).

10 Commensal *Prevotella* species are frequent colonizers of the lower and upper airways; however little
11 is known about the inflammatory properties of these bacterial species in the respiratory system. Since
12 pathogenic Proteobacteria are recognized co-drivers of chronic airway inflammation in COPD and have
13 been studied in relevant murine models of the disease, we here compared these to the commensal
14 *Prevotella* spp. We demonstrate weak innate stimulatory properties of Gram-negative commensal
15 *Prevotella* spp. that may make colonization by these bacteria tolerable by the respiratory immune system.
16 On the contrary, the innate stimulatory capacity of pathogenic Proteobacteria likely allow these bacteria to
17 be specific co-drivers of disease progression in COPD and asthma patients.

18

1 **Materials and Methods**

2 **Mice**

3 Wild-type C57BL/6J mice were obtained from Taconic (Silkeborg, Denmark). TLR2 deficient mice on
4 the C57BL/6J background were obtained from Jackson Laboratories (Bar Harbor, ME) and bred in-house.
5 Mice were kept under specific pathogen free conditions, according to national guidelines for experimental
6 animal housing and under the daily care by animal technicians. All experiments were carried out using sex
7 and age-matched mice. The experimental protocols were approved by the Danish Animal Ethics Committee
8 (permission number: 2007/561-1266).

9

10 **Bacteria growth and preparation**

11 *Haemophilus influenzae* B (KAK510), *Haemophilus influenzae* NT (KAK509) and *Moraxella catarrhalis*
12 F48 (KAK508) reference strains were kindly provided by Karen A. Krogfelt and Jørgen Skov Jensen, Statens
13 Serum Institut, Copenhagen, Denmark. *Prevotella melaninogenica* (DSM7089), *Prevotella nanceiensis*
14 (DSM19126) and *Prevotella salivae* (DSM15606) were obtained from Deutsche Sammlung von
15 Mikroorganismen und Zellkulturen (DSMZ), Braunschweig, Germany. *Haemophilus* and *Moraxella* strains
16 were grown on chocolate agar plates (Statens Serum Institut) under 37°C microaerobic (5% CO₂)
17 conditions. *Prevotella* strains were grown on anaerobic agar plates (Statens Serum Institut) under 30°C
18 anaerobic conditions. All strains were resuspended from plates with uniform growth and washed once in
19 PBS. Bacteria were resuspended in PBS to OD 1 and UV-irradiated for 45 minutes. UV killing were confirmed
20 by plating. Dry weight of bacterial suspensions in PBS was determined on 3x1 ml portions after freeze-
21 drying (subtracted by weight of PBS). Bacterial suspensions were frozen and stored at -80°C.

22 Colony forming units (CFU) were determined in bacterial suspensions before UV-irradiation using
23 serial dilution. CFUs pr. bacterial dry weight were as follows: 7.81×10^5 CFU/ug (H. inf. B), 4.91×10^5 CFU/ug
24 (H. inf. NT), 2.45×10^5 CFU/ug (M. cat.), 0.26×10^5 CFU/ug (P. mel.), 0.13×10^5 CFU/ug (P. nan.) and $0.15 \times$
25 10^5 CFU/ug (P. sal.).

1

2 **Primary lung cell preparation and stimulation**

3 Mice were anesthetized using Ketamine/Xylazine (10/0.5 mg pr. 50 g body weight; Intervet,
4 Boxmeer, Holland) and euthanized by heart puncture blood removal. PBS was perfused through the heart
5 to remove systemic blood. Lungs were excised, cut into 1-2 mm pieces and incubated for 1h at 37°C in PBS
6 (Lonza, Basel, Switzerland) supplemented with 30U/ml *Clostridium histolyticum* collagenase type II and 150
7 µg/ml DNAase (Sigma-Aldrich, Copenhagen, Denmark). The tissues were passed through a 70 µm cell
8 strainer (BD Bioscience) to obtain a single cell suspension of lung cells. Cells from lungs of 3-5 mice were
9 pooled and separated into lung constituent cells (CD45-) and lung leukocytes (CD45+) using a CD45+
10 magnetic cell sorting kit (MACS; MiltenyiBiotec, Bergisch Gladbach, Germany) according to manufacturer's
11 recommendations. Purity was confirmed by flow cytometry. Cells were resuspended in complete RPMI
12 1640 medium (Lonza, Basel, Switzerland; supplemented with 2 mM L-glutamine (Cambrex, East Rutherford,
13 NJ), 100 U/ml penicillin/streptomycin (Lonza) and 10 % FCS (Lonza)) and plated in 96-well plates ($2 \cdot 10^5$
14 cells/well). In experiments with mixed CD45- and CD45+ lung cells a ratio of 1:1 was used.

15 Primary lung cells were stimulated with 50 µg/ml of bacterial preparations supplemented with 50
16 µg/ml gentamycin (Sigma-Aldrich) to ensure no bacterial outgrowth. LPS (100 ng/ml) and medium alone
17 were included to serve as a positive and negative control, respectively. All stimulations were done in
18 triplicates. Supernatants were harvested after 24 hours and stored at -80°C until cytokine analyses.

19

20 **Acute airway inflammation model**

21 Mice were lightly sedated using Ketamine/Xylazine (5 mg/0.25 mg pr. 50 g body weight). While kept
22 in a vertical position, 25 µl bacterial suspension or vehicle (PBS) alone was inhaled through each nostril
23 giving a final dose of 22.5 µg bacteria in 50 µl (450 µg/ml). Mice were kept vertical for 1 minute following
24 inhalation.

1 24 hours after bacterial inhalation, the mice were anesthetized using Ketamine/Xylazine (10 mg/0.5
2 mg pr. 50g body weight) and euthanized by heart puncture. Bronchoalveolar lavage (BAL) cells were
3 collected by perfusing lungs with 800 μ l PBS five times. Right lung was snap frozen in liquid nitrogen and
4 stored at -80°C until measurement of tissue cytokines. Left lung was embedded in Tissue-tek OCT
5 Compound (Sakura, Tokyo, Japan) and stored at -80°C until histochemical analysis.

6

7 **Tissue and supernatant cytokine measurements**

8 Measurement of cytokine production in tissue was performed as previously described.(31) Frozen
9 lung tissue were homogenized in a mortar with 500 μ l/mg tissue PBS contain 0.1% Tween-20 (v/v) and
10 protease inhibitor cocktail (Complete, Roche, 1 tablet/50 ml PBS). Tissue homogenates were frozen in liquid
11 nitrogen, thawed, sonicated for 30s and centrifuged to remove debris. Lysates were stored at -80°C until
12 cytokine analysis by ELISA.

13 Cytokines were measured in lung tissue homogenates and supernatants from cell cultures using
14 commercial ELISA kits (IL-5, IL-4 and IL-13 from eBioscience, San Diego, CA; MIP-2 α (IL-8), TSLP, TNF α , IL-10,
15 IFN γ , IL-17, CCL20, CXCL16, IL-1 β , IL-6 and IL-10 from RnD Systems, Minneapolis, MN) according to
16 manufacturer's recommendations.

17

18 **Flow cytometry**

19 The composition of BAL cells was analyzed by flow cytometry as previously described(32) using the
20 following anti-mouse fluorochrome-conjugated antibodies: Anti-CD45/eFlour450, anti-CD11b/FITC, anti-
21 CD11c/APC (eBioscience), anti-Siglec-F/PE (BD Bioscience), anti-Gr-1/APC-Cy7 and anti-mF4/80/PE-Cy7
22 (Biolegend). Staining was performed in PBS containing 1 % FCS, 0.1 % sodium azide and Fc-block (BD
23 Bioscience) for 30 minutes at 4°C . Cells were analyzed on a BD FACSCanto™ II system running FACSdiva 6.0
24 software (BD Biosciences, San Jose, CA). Immune cells were identified among CD45+ leukocytes as follows:
25 Eosinophils (CD11c-, Siglec-F+), lymphocytes (CD11b-CD11c-), macrophages (F4/80+Gr-1-), neutrophils

1 (F4/80-Gr-1+), monocytes (F4/80-Gr-1-CD11bintCD11c-), CD11b+ dendritic cells (CD11b+ DCs; F4/80-Gr-1-
2 CD11b+CD11c+) and CD11b-/low dendritic cells (CD11b-/low DCs; F4/80-Gr-1-CD11bintCD11c+). Flow
3 cytometry data was analyzed using FlowJo 7.6.5 (Tree Star, Ashland, OR).

5 **Histochemical staining**

6 Tissue-tek OCT Compound embedded lung tissues were thawed overnight in 4 % (v/v) para-
7 formaldehyde/PBS at 4°C. Tissues were embedded in paraffin and cut into 5 µm sections. Sections were
8 stained by Mayer's haematoxylin and eosin (Pioneer research chemicals, Colchester, UK) and evaluated by
9 microscopy. Two pictures were taken representing areas with most and least inflammation in each lung
10 section. Both pictures were used to grade lung pathology giving an average score. Pathology scores were
11 given on a relative scale (1 – 6) judging integrity of the bronchial epithelium, peri-bronchial/arterial
12 inflammation, as well as alveolar integrity and inflammation. Pathology scoring was performed in a blinded
13 manner.

15 **Data analysis and statistics**

16 Statistical analysis was performed using GraphPad PRISM 5.01 (GraphPad Software, La Jolla, CA).
17 Differences in BAL cell composition, cytokines levels in lung tissue and pathology scores were analyzed by
18 two-way ANOVA and post-hoc by Bonferroni's multiple comparison test. Cytokine production in lung tissue
19 was reported after subtracting mean levels measured in tissue from PBS treated mice (background).
20 Student's one-sample t-test was applied to test if a cytokine was induced in the lung tissue after bacterial
21 challenge (testing if mean level different from 0 ng/g lung tissue). Differences in the capacity of pathogenic
22 Proteobacteria and *Prevotella* spp to induce cytokine production in primary lung cells *in vitro* was analyzed
23 in a compartmentalized manner using Student's t-test comparing data from the three bacteria in each
24 phylum. Bar charts show mean and standard error of the mean (SEM). P-values below 0.05 were
25 considered statistically significant. P-values are indicated as follows: *, p < 0.05; **, p < 0.01; ***, p < 0.001.

26

1 Results

2 Lung commensal *Prevotella* spp exhibit distinct inflammatory properties compared to COPD and asthma- 3 associated Proteobacteria

4 Three bacterial strains representing the COPD and asthma-associated Proteobacteria, as well as
5 three *Prevotella* spp associated with healthy lungs were chosen for an initial analysis of innate
6 inflammatory properties on primary murine lung cells. *Haemophilus influenzae* and *Moraxella catarrhalis*
7 (*M. cat.*) were selected as the key members of pathogenic Proteobacteria bacteria associated with COPD
8 and asthma. It was decided to include the *Haemophilus influenzae* B (*H. inf. B*) and non-typeable
9 *Haemophilus influenzae* (*H. inf. NT*) strains, as these common strains are structurally different due to the
10 presence or absence of bacterial capsule, respectively (33, 34). *Prevotella melaninogenica* (*P. mel.*),
11 *Prevotella nanceiensis* (*P. nan.*) and *Prevotella salivae* (*P. sal.*) were included as representative commensal
12 *Prevotella* spp predominantly associated with healthy airways (7, 11). The innate inflammatory capacities of
13 the Proteobacteria and *Prevotella* spp were addressed by stimulating primary CD45+ and CD45- cells
14 isolated from murine lungs representing lung leukocytes and non-immune cells, respectively. The
15 production of key acute-phase cytokines MIP-2 α (IL-8) and TNF α known to be involved in COPD and asthma
16 pathology were analyzed in supernatants (35). IL-10 was analyzed to address potential anti-inflammatory
17 aspects of the bacterial response. TSLP production was addressed as a cytokine produced exclusively by
18 epithelial cells, and involved in priming of type-2 immune responses (36). In addition, cytokines IL-5, IL-4
19 and IL-13 were analyzed to assess potential type-2 immune responses induced by the bacteria. Co-cultures
20 of CD45+ and CD45- cells (1:1) were performed to examine possible cytokine-enhancing cross talk between
21 these cellular compartments.

22 We observed significant differences between the cytokine profiles induced in primary murine lung
23 cells by the COPD and asthma-associated Proteobacteria and the commensal *Prevotella* spp (figure 1A).
24 *Prevotella* spp generally induced lower cytokine production compared to Proteobacteria, but the
25 observation was dependent on the cytokine investigated and the cellular compartment. In CD45+ lung cells,

1 *Prevotella* spp induced lower TNF α production compared to the three Proteobacteria. Additionally, TNF α ,
2 MIP-2 α (IL-8) and TSLP were lower for *Prevotella* spp in the CD45- compartment. These cytokines and IL-10
3 were also produced less in response to *Prevotella* spp in 1:1 co-cultures of CD45+ and CD45- cells isolated
4 from murine lungs (figure 1A). Interestingly, measurements of MIP-2 α (IL-8) production indicated a
5 synergistic effect between CD45+ and CD45- cells giving rise to generally higher MIP-2 α (IL-8) levels in co-
6 cultures. It is observed that production of some cytokines is restricted to a particular compartment.
7 Expectedly, TSLP was only produced in CD45- lung cells, as this is an epithelial-derived cytokine (36). IL-5
8 production was absent in the CD45- compartment indicating this cytokine is only produced by lung immune
9 cells. Furthermore, MIP-2 α (IL-8), TNF α and IL-10 were generally lower in the non-immune CD45- lung cell
10 compartment. IL-4 and IL-13 production in response to the bacteria could not be detected in bacteria-
11 exposed CD45+ or CD45- lung cells (data not shown).

12 The observed differences in innate immune stimulatory properties between the three COPD and
13 asthma-associated Proteobacteria and the commensal *Prevotella* spp could be due to differences in
14 concentrations of specific innate ligands (microbe-associated molecular patterns, MAMPs) shared by the
15 bacteria. To test this, we stimulated primary lung cells isolated from mice with increasing concentrations of
16 the three Proteobacteria and *Prevotella* spp. TNF α and TSLP were measured as representative cytokines
17 with observed differences in production induced by the two groups of bacteria in the CD45+ and CD45-
18 lung cells compartments, respectively. The cytokine response to increasing concentrations of bacteria from
19 the Proteobacteria and *Prevotella* spp fitted well to a one-site saturation binding equation (figure 1B).
20 There was a significant difference in the maximum capacity of the Proteobacteria and *Prevotella* spp to
21 induce innate stimulation in lung cells (TNF α from CD45+ lung cells, Bmax 1378 pg/ml vs. 1021 pg/ml, $p <$
22 0.0001; TSLP from CD45- lung cells, Bmax 53.2 pg/ml vs. 30.5 pg/ml, $p <$ 0.0001). These findings
23 demonstrate intrinsic innate stimulatory divergence between the three COPD and asthma-associated
24 Proteobacteria and commensal *Prevotella* spp likely due to differences in composition of microbial-
25 associated molecular patterns (MAMPs) with alternating capacity to activate innate immune receptors.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

**COPD and asthma-associated non-typeable *Haemophilus influenzae*, but not *Prevotella nanceiensis*,
potently induce airway inflammation and pathology in mice**

Airway challenge with *Haemophilus influenzae* has been shown to induce inflammatory aspects of COPD in lungs of mice, including production of acute phase cytokines TNF α , IL-6 and IL-1 β , airway neutrophilia and tissue pathology (30). We sought to investigate how the intrinsic differences in immune stimulatory capacity between the three Proteobacteria and *Prevotella* spp may translate to the presentation of COPD- and/or asthma-like airway inflammation *in vivo*. We challenged mice with *Haemophilus influenzae* (H. inf. NT) and *Prevotella nanceiensis* (P. nan.) as representative strains of the two groups of bacteria. Airways challenged with H. inf. NT induced predominant recruitment of neutrophils as demonstrated by flow cytometry analysis of BAL cells (figure 2A and 2B). No statistically significant recruitment of eosinophils, lymphocytes, macrophages, monocytes or dendritic cell subsets could be observed. We analyzed a panel of acute-phase cytokines and chemokines (MIP-2 α (IL-8), IL-6, IL-1 β , TNF α) known to be associated with airway inflammation (35, 37). Furthermore, the analysis included cytokines and chemokines associated with type-17 (IL-17, CCL20) responses, type-1 (IFN γ) responses, type-2 (IL-5, TSLP) responses, immune regulation (IL-10) and recruitment of T cells to the lung (CXCL16) (38). The airway neutrophilia induced by H. inf. NT was accompanied by production of CCL20, CXCL16, IL-1 β , IL-6 and MIP-2 α (IL-8), and to lesser extent IFN γ and TNF α in lung tissue (significant induction by Student's one-sample t-test; figure 2C). The induced cytokines and chemokines relate primarily to type-17 inflammation and neutrophil recruitment; however induction of the prototype type-17 cytokine IL-17, as well as IL-10, TSLP and IL-5 were not detectable in the lung tissue. Immunohistochemical analysis revealed that the airway inflammation mediated by H. inf. NT was accompanied by lung pathology characterized by massive peribronchial inflammation, recruitment of immune cells and destruction of alveolar integrity (figure 2D and 2E).

1 P. nan. was found to induce some airway neutrophil recruitment which was 3-4 fold lower than the
2 recruitment mediated by H. inf. NT (figure 2B). The decreased airway inflammation by P. nan. was
3 associated with significant decrease in the acute-phase cytokine IL-1 β , and the neutrophilic chemokines
4 CCL20 and MIP-2 α (IL-8) as compared to H. inf. NT (figure 2C). No lung tissue pathology could be detected
5 following airway challenge with P. nan. (figure 2D and 2E). These findings suggest that *Prevotella* spp
6 associated with healthy lungs may be intrinsically tolerated by the respiratory immune system, whereas
7 pathogenic Proteobacteria exhibit distinct properties that can mediate COPD-like inflammatory features.

8

9 **A different role for TLR2 in airway inflammation mediated by non-typeable *Haemophilus Influenzae* and** 10 ***Prevotella nanceiensis***

11 Toll-like receptors (TLRs) play an important role in mediating inflammation by recognizing conserved
12 MAMPs. TLR4 is the receptor for LPS, a molecule classical viewed as the most potent MAMP found in Gram-
13 negative bacteria. Activation of TLR4 and TLR2 has been reported to account for up to 90 % of the
14 inflammatory response to common pathogenic Gram-negative bacteria (39). Both the Proteobacteria and
15 *Prevotella* spp analyzed in this study are Gram-negative and contain LPS with the potential to activate TLR4.
16 However, the two groups of bacteria may have different TLR4 activating properties. This is exemplified by,
17 the gut commensal Gram-negative *Bacteroides fragilis* of the same phylum as the *Prevotella* spp
18 (Bacteroidetes), which have been shown to activate TLR2, but not TLR4 (40). It is possible to address the
19 contribution of TLR2 in TLR2 KO mice, and hence indirectly examine the contribution from other ligands,
20 such as LPS (TLR4). The role of TLR2 in the airway inflammatory response to *Haemophilus influenzae* (H. inf.
21 NT) and *Prevotella nanceiensis* (P. nan.) was compared using WT and TLR2^{-/-} mice. We found TLR2 to be
22 dispensable for acute airway neutrophilia and lung tissue pathology mediated by H. inf. NT (figure 3A and
23 3C). However, MIP-2 α (IL-8) production in the lung in response to H. inf. NT was diminished in TLR2-
24 deficient mice (figure 3B), indicating that MIP-2 α (IL-8) is not essential for full expression of airway
25 neutrophilia.

1 Airway inflammation mediated by *P. nan.* was found to be completely dependent on TLR2. Cellular
2 recruitment in airways was absent (no difference when compared to PBS-treated group) and none of the
3 analyzed cytokines were found to be induced (tested by Student's one-sample t-test) in response to *P. nan.*
4 in TLR2-deficient mice (figure 3A and 3B). Expectedly, also TLR2-deficient mice showed no lung pathology in
5 response to *P. nan.* (figure 3C). These findings indicate that the innate stimulatory potential of *Prevotella*
6 spp is mainly related to TLR2 activation, whereas pathogenic Proteobacteria stimulate via other immune
7 receptors that can fully express COPD-like inflammatory features.

8

1 Discussion

2 The present study demonstrates intrinsic differences in innate stimulatory and airway inflammatory
3 properties between pathogenic Proteobacteria associated with chronic inflammatory airway disease (COPD
4 and asthma) and commensal *Prevotella* spp associated with healthy lungs.

5 Bacteria contain several conserved compounds including the MAMPs that cause immune activation
6 via innate receptors. LPS is a well known ubiquitous cell membrane constituent of all Gram-negative
7 bacteria and is classically viewed as a potent MAMP for innate immune activation via TLR4. Studies have
8 shown that TLR4 and TLR2 account for approximate 90 % of the pro-inflammatory innate response of
9 human leucocytes to common pathogenic Gram-negative bacteria (39). Here we found that airway
10 inflammation driven by *Prevotella* spp was completely dependent on TLR2. This finding suggests that
11 *Prevotella* spp do not contain immunostimulatory LPS that can mediate airway inflammation. Indeed, the
12 difference in inflammatory potential between the Gram-negative COPD and asthma-associated
13 Proteobacteria and commensal *Prevotella* spp can likely be ascribed to differences in LPS structures (41). It
14 is known that tetra- and penta-acylated LPS structures retain lower stimulatory activity on TLR4 than hepta-
15 and hexa-acylated LPS (42, 43). The prototypic hexa-acylated LPS of *E. coli* seems to be the most biologically
16 potent structure, whereas LPS with fewer and shorter acyl-chains have lower capacity to stimulate TLR4
17 (44–46). *Haemophilus influenzae* and *Moraxella catarrhalis* has been reported to contain hexa- and hepta-
18 acylated LPS, respectively (47, 48). On the contrary, *Prevotella* spp and other members of the Bacteroidetes
19 phylum have been reported to contain penta-acylated LPS, which have implications for recognition of the
20 bacteria by TLR4. LPS isolated from the oral commensal *Prevotella intermedia* demonstrate approximate
21 10-fold reduced potency to induce IL-6 in murine macrophages as compared to *E. coli* LPS (49).
22 Furthermore, the gut commensal *Bacteroides fragilis* contain penta-acylated LPS (50), and this bacterium
23 has been found to stimulate TLR2 but not TLR4 (40). The presence of immune inactive LPS in all *Prevotella*
24 spp is supported by a recent bioinformatic-based analysis performed by our group. We analyzed all
25 sequenced bacterial genomes publicly available and studied the genes involved in LPS synthesis. We found

1 that the *LpxM* gene encoding the enzyme (KDO)₂-(lauroyl)-lipid IVA acyltransferase needed to add a 6th acyl
2 chain to lipid A (important for TLR4 immune activity) is absent in all members of the Bacteroidetes phylum
3 including *Prevotella* spp, but present in gamma-Proteobacteria such as *H. influenzae* (Brix *et al.*, manuscript
4 in revision).

5 In the present report, *Prevotella* spp associated with healthy human lungs was well-tolerated in
6 murine airways by inducing limited neutrophilia, chemokine and cytokine production, as well as provoking
7 no detectable lung immunopathology as compared to pathogenic Proteobacteria. Observational studies
8 reporting lung dysbiosis with increased pathogenic proteobacteria and reduced *Prevotella* spp. in COPD and
9 asthma (7) suggest that the well-tolerated *Prevotella* spp serves a disease-protective role. A protective role
10 of *Prevotella* spp. could be ascribed to 1) a direct modulation of innate immune responses in the lung, 2)
11 induction of functional and developmental changes in the immune system, 3) suppression of
12 Proteobacterial colonization or infection by taking up a ecological niche in the microbiota, and 4) direct
13 killing of Proteobacteria. Interestingly, a recent study in mice reported that the acquisition of a
14 Bacteroidetes-rich lung microbiota during early life was associated with the establishment of tolerance in
15 the lung and suppression of allergic inflammation, whereas Proteobacterial-rich lungs of neonatal mice
16 showed exaggerated responses to allergen (51). Additionally, we have previously reported that *Prevotella*
17 spp. modulates the *in vitro* inflammatory response of human dendritic cells to *Haemophilus influenzae*
18 suggesting that members of the commensal lung microbiota may directly limit the immune response to
19 specific pathogens (41). Additional studies are needed to establish if *Prevotella* spp. exhibit causal disease-
20 protective effects.

21 We found that the three Proteobacteria associated with COPD and asthma potently mediated airway
22 neutrophilia, inflammatory chemokine/cytokine production and tissue pathology in mice. This is in line with
23 previous studies reporting, that certain Proteobacteria can induce COPD-like inflammatory features and
24 promote COPD disease in murine models (28–30). The results from murine studies support the notion of
25 pathogenic Proteobacteria as potential co-drivers of COPD disease (21–24). We speculate that it is the

1 specific immune active hexa-acylated structure of LPS in these bacterial strains that gives the bacteria its
2 disease-promoting activity. Indeed, inhalation of LPS in humans mediates production of IL-1 β , IL-6 and
3 TNF α , neutrophil recruitment and decreased lung function (FEV1) (52, 53). Based on these findings it could
4 be proposed to examine the applicability of inhaled TLR4 antagonists as an option for treatment of chronic
5 inflammatory airway disease with involvement of pathogenic Proteobacteria.

1 **Acknowledgments**

2 The authors thank animal technician Pernille Wehler Güllich and laboratory technician Lisbeth Buus
3 Rosholm for their excellent assistance and support during this study.

4 JML conceived the study, designed experiments, analyzed data and wrote the manuscript. HSM and
5 TMB performed experiments and analyzed data. CI performed histological staining and scoring. SB
6 supervised the study. All authors provided important intellectual contributions to the study and writing of
7 manuscript.

8 Funding from the Lundbeck Foundation and the A. P. Møller Foundation for the Advancement of
9 Medical Science is highly acknowledged. The funding bodies had no role in study design; in the collection,
10 analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the
11 manuscript for publication.

12

13 **Conflict of Interest**

14 The authors have no financial or commercial conflicts of interest to disclose in relation to publication
15 of the manuscript.

16

1 **Figure legends**

2 **FIGURE 1: Inflammatory response of murine lung cells to three airway-related Proteobacteria and**
3 ***Prevotella* spp.**

4 MIP-2 α (IL-8), TNF α , IL-10, TSLP and IL-5 production by primary CD45+, CD45- or mixed CD45+/- (1:1) cells
5 isolated from murine lungs in response to 24h stimulation with medium, LPS, three Proteobacteria or
6 *Prevotella* spp (A). Dose-response titration of Proteobacteria and *Prevotella* spp on primary murine lung
7 cells (B). Data represents one of four (A) and two (B) independent experiments (n = 3, mean + SEM).

8

9 **FIGURE 2: Airway inflammation following challenge with *Haemophilus influenzae* or *Prevotella***
10 ***nanceiensis* in mice.**

11 Flow cytometry of BAL cells (A), absolute cell numbers in BAL (B), chemokine/cytokine levels in lung tissue
12 homogenates (C), representative HE-stained lung tissue sections (D), and pathology scores (E) obtained
13 from murine lungs 24h after airway challenge with vehicle (PBS), *Haemophilus influenzae* or *Prevotella*
14 *nanceiensis*. Data represents two independent experiments (n = 8, mean + SEM).

15

16 **FIGURE 3: The role of TLR2 in the airway inflammatory response to *Haemophilus influenzae* or *Prevotella***
17 ***nanceiensis* in mice.**

18 Absolute cell numbers in BAL (A), chemokine/cytokine levels in lung tissue homogenates (B), and pathology
19 scores (C) obtained from WT or TLR2-/- murine lungs 24h after airway challenge with *Haemophilus*
20 *influenzae* or *Prevotella nanceiensis*. Data represents two independent experiments (n = 8, mean + SEM).

1 References

- 2 1. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota
3 and immune system. *Nature* 2012;489:231–41.
- 4 2. Kamada N, Seo S-U, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory
5 disease. *Nat Rev Immunol* 2013;13:321–35.
- 6 3. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism.
7 *Nature* 2012;489:242–9.
- 8 4. Kahn FW, Jones JM. Diagnosing bacterial respiratory infection by bronchoalveolar lavage. *J Infect Dis*
9 1987;155:862–9.
- 10 5. Baughman R, Thorpe J, Staneck J, Rashkin M, Frame P. Use of the protected specimen brush in
11 patients with endotracheal or tracheostomy tubes. *Chest* 1987;91:233–236.
- 12 6. Thorpe JE, Baughman RP, Frame PT, Wesseler TA, Staneck JL. Bronchoalveolar lavage for diagnosing
13 acute bacterial pneumonia. *J Infect Dis* 1987;155:855–61.
- 14 7. Hilty M, Burke C, Pedro H, Cardenas P, Bush A, Bossley C, Davies J, Ervine A, Poulter L, Pachter L,
15 Moffatt MF, Cookson WOC. Disordered microbial communities in asthmatic airways. *PLoS One*
16 2010;5:e8578.
- 17 8. Charlson ES, Chen J, Custers-Allen R, Bittinger K, Li H, Sinha R, Hwang J, Bushman FD, Collman RG.
18 Disordered microbial communities in the upper respiratory tract of cigarette smokers. *PLoS One*
19 2010;5:e15216.
- 20 9. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt L a, Young VB, Toews
21 GB, Curtis JL, Sundaram B, Martinez FJ, Huffnagle GB. Analysis of the lung microbiome in the
22 “healthy” smoker and in COPD. *PLoS One* 2011;6:e16384.
- 23 10. Harris JK, De Groote MA, Sagel SD, Zemanick ET, Kapsner R, Penvari C, Kaess H, Deterding RR,
24 Accurso FJ, Pace NR. Molecular identification of bacteria in bronchoalveolar lavage fluid from
25 children with cystic fibrosis. *Proc Natl Acad Sci U S A* 2007;104:20529–33.
- 26 11. Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank I, Yadav A, Bushman FD, Collman RG.
27 Topographical continuity of bacterial populations in the healthy human respiratory tract. *Am J Respir*
28 *Crit Care Med* 2011;184:957–63.
- 29 12. Nagy E. Anaerobic infections: update on treatment considerations. *Drugs* 2010;70:841–58.
- 30 13. Brook I. Anaerobic pulmonary infections in children. *Pediatr Emerg Care* 2004;20:636–40.
- 31 14. Brook I. Microbiology of common infections in the upper respiratory tract. *Prim Care* 1998;25:633–
32 48.
- 33 15. Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune
34 responses. *Cell Host Microbe* 2011;10:311–23.

- 1 16. Goleva E, Jackson LP, Harris JK, Robertson CE, Sutherland ER, Hall CF, Good JT, Gelfand EW, Martin
2 RJ, Leung DYM. The effects of airway microbiome on corticosteroid responsiveness in asthma. *Am J*
3 *Respir Crit Care Med* 2013;188:1193–201.
- 4 17. Bisgaard H, Hermansen MN, Buchvald F, Loland L, Halkjaer LB, Bønnelykke K, Brasholt M, Heltberg A,
5 Vissing NH, Thorsen SV, Stage M, Pipper CB. Childhood asthma after bacterial colonization of the
6 airway in neonates. *N Engl J Med* 2007;357:1487–95.
- 7 18. Murphy TF, Sethi S, Niederman MS. The role of bacteria in exacerbations of COPD. A constructive
8 view. *Chest* 2000;118:204–9.
- 9 19. Monsó E, Rosell A, Bonet G, Manterola J, Cardona PJ, Ruiz J, Morera J. Risk factors for lower airway
10 bacterial colonization in chronic bronchitis. *Eur Respir J Off J Eur Soc Clin Respir Physiol*
11 1999;13:338–42.
- 12 20. Zalacain R, Sobradillo V, Amilibia J, Barrón J, Achótegui V, Pijoan JI, Llorente JL. Predisposing factors
13 to bacterial colonization in chronic obstructive pulmonary disease. *Eur Respir J Off J Eur Soc Clin*
14 *Respir Physiol* 1999;13:343–8.
- 15 21. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive
16 pulmonary disease. *Proc Am Thorac Soc* 2006;3:245–51.
- 17 22. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and
18 markers of airway inflammation in patients with stable chronic bronchitis. *Am J Med* 2000;109:288–
19 95.
- 20 23. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1
21 decline in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*
22 2003;167:1090–5.
- 23 24. Sethi S, Maloney J, Grove L, Wrona C, Berenson CS. Airway inflammation and bronchial bacterial
24 colonization in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2006;173:991–8.
- 25 25. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, Curtis JL, Dransfield MT, Han MK,
26 Lazarus SC, Make B, Marchetti N, Martinez FJ, Madinger NE, McEvoy C, Niewoehner DE, Porsasz J,
27 Price CS, Reilly J, Scanlon PD, Sciurba FC, Scharf SM, Washko GR, Woodruff PG, Anthonisen NR.
28 Azithromycin for prevention of exacerbations of COPD. *N Engl J Med* 2011;365:689–98.
- 29 26. Bisgaard H, Hermansen MN, Bønnelykke K, Stokholm J, Baty F, Skytt NL, Aniscenko J, Kebabdz T,
30 Johnston SL. Association of bacteria and viruses with wheezy episodes in young children:
31 prospective birth cohort study. *BMJ* 2010;341:c4978.
- 32 27. Larsen JM, Brix S, Thysen AH, Birch S, Rasmussen MA, Bisgaard H. Children with asthma by school
33 age display aberrant immune responses to pathogenic airway bacteria as infants. *J Allergy Clin*
34 *Immunol* 2014;133:1008–1013.e4.
- 35 28. Gaschler GJ, Skrtic M, Zavitz CCJ, Lindahl M, Onnervik P-O, Murphy TF, Sethi S, Stämpfli MR. Bacteria
36 challenge in smoke-exposed mice exacerbates inflammation and skews the inflammatory profile.
37 *Am J Respir Crit Care Med* 2009;179:666–75.

- 1 29. Gaschler GJ, Zavitz CCJ, Bauer CMT, Stämpfli MR. Mechanisms of clearance of nontypeable
2 Haemophilus influenzae from cigarette smoke-exposed mouse lungs. *Eur Respir J Off J Eur Soc Clin*
3 *Respir Physiol* 2010;36:1131–42.
- 4 30. Moghaddam SJ, Clement CG, De la Garza MM, Zou X, Travis EL, Young HWJ, Evans CM, Tuvim MJ,
5 Dickey BF. Haemophilus influenzae lysate induces aspects of the chronic obstructive pulmonary
6 disease phenotype. *Am J Respir Cell Mol Biol* 2008;38:629–38.
- 7 31. Bonefeld CM, Larsen JM, Dabelsteen S, Geisler C, White IR, Menné T, Johansen JD. Consumer
8 available permanent hair dye products cause major allergic immune activation in an animal model.
9 *Br J Dermatol* 2010;162:102–7.
- 10 32. Dyer KD, Garcia-Crespo KE, Killoran KE, Rosenberg HF. Antigen profiles for the quantitative
11 assessment of eosinophils in mouse tissues by flow cytometry. *J Immunol Methods* 2011;369:91–7.
- 12 33. Pittman M. Variation and type specificity in the bacterial species Hemophilus influenzae. *J Exp Med*
13 1931;53:471–92.
- 14 34. Geme JWS. Molecular and cellular determinants of non-typeable Haemophilus influenzae adherence
15 and invasion. *Cell Microbiol* 2002;4:191–200.
- 16 35. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-
17 alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. *Am J*
18 *Respir Crit Care Med* 1996;153:530–4.
- 19 36. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, Gilliet M, Ho S, Antonenko S,
20 Lauerma A, Smith K, Gorman D, Zurawski S, Abrams J, Menon S, McClanahan T, de Waal-Malefyt Rd
21 R, Bazan F, Kastelein RA, Liu Y-J. Human epithelial cells trigger dendritic cell mediated allergic
22 inflammation by producing TSLP. *Nat Immunol* 2002;3:673–80.
- 23 37. Chung KF. Cytokines in chronic obstructive pulmonary disease. *Eur Respir J Suppl* 2001;34:50s–59s.
- 24 38. Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6
25 expression by lung CD8+ cells correlates with chronic obstructive pulmonary disease severity. *Am J*
26 *Pathol* 2007;171:767–76.
- 27 39. Elson G, Dunn-Siegrist I, Daubeuf B, Pugin J. Contribution of Toll-like receptors to the innate immune
28 response to Gram-negative and Gram-positive bacteria. *Blood* 2007;109:1574–83.
- 29 40. Alhawi M, Stewart J, Erridge C, Patrick S, Poxton IR. Bacteroides fragilis signals through Toll-like
30 receptor (TLR) 2 and not through TLR4. *J Med Microbiol* 2009;58:1015–22.
- 31 41. Larsen JM, Steen-Jensen DB, Laursen JM, Søndergaard JN, Musavian HS, Butt TM, Brix S. Divergent
32 pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic
33 bacteria associated with the airway microbiota. *PLoS One* 2012;7:e31976.
- 34 42. Bäckhed F, Normark S, Schweda EKH, Oscarson S, Richter-Dahlfors A. Structural requirements for
35 TLR4-mediated LPS signalling: a biological role for LPS modifications. *Microbes Infect* 2003;5:1057–
36 63.

- 1 43. Miller SI, Ernst RK, Bader MW. LPS, TLR4 and infectious disease diversity. *Nat Rev Microbiol*
2 2005;3:36–46.
- 3 44. Lebeer S, Vanderleyden J, De Keersmaecker SCJ. Host interactions of probiotic bacterial surface
4 molecules: comparison with commensals and pathogens. *Nat Rev Microbiol* 2010;8:171–84.
- 5 45. Caroff M, Karibian D. Structure of bacterial lipopolysaccharides. *Carbohydr Res* 2003;338:2431–47.
- 6 46. Caroff M, Karibian D, Cavaillon JM, Haeffner-Cavaillon N. Structural and functional analyses of
7 bacterial lipopolysaccharides. *Microbes Infect* 2002;4:915–26.
- 8 47. Schweda EKH, Twelkmeyer B, Li J. Profiling structural elements of short-chain lipopolysaccharide of
9 non-typeable *Haemophilus influenzae*. *Innate Immun* 2008;14:199–211.
- 10 48. Masoud H, Perry MB, Richards JC. Characterization of the lipopolysaccharide of *Moraxella*
11 *catarrhalis*. Structural analysis of the lipid A from *M. catarrhalis* serotype A lipopolysaccharide. *Eur J*
12 *Biochem* 1994;220:209–16.
- 13 49. Hashimoto M, Asai Y, Tamai R, Jinno T, Umatani K, Ogawa T. Chemical structure and
14 immunobiological activity of lipid A from *Prevotella intermedia* ATCC 25611 lipopolysaccharide. *FEBS*
15 *Lett* 2003;543:98–102.
- 16 50. Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR. Lipopolysaccharides of *Bacteroides fragilis*,
17 *Chlamydia trachomatis* and *Pseudomonas aeruginosa* signal via toll-like receptor 2. *J Med Microbiol*
18 2004;53:735–40.
- 19 51. Gollwitzer ES, Saglani S, Trompette A, Yadava K, Sherburn R, McCoy KD, Nicod LP, Lloyd CM,
20 Marsland BJ. Lung microbiota promotes tolerance to allergens in neonates via PD-L1. *Nat Med*
21 2014;20:642–7.
- 22 52. Hernandez ML, Herbst M, Lay JC, Alexis NE, Brickey WJ, Ting JPY, Zhou H, Peden DB. Atopic
23 asthmatic patients have reduced airway inflammatory cell recruitment after inhaled endotoxin
24 challenge compared with healthy volunteers. *J Allergy Clin Immunol*
25 2012;doi:10.1016/j.jaci.2012.05.026.
- 26 53. Möller W, Heimbeck I, Hofer TPJ, Khadem Saba G, Neiswirth M, Frankenberger M, Ziegler-Heitbrock
27 L. Differential inflammatory response to inhaled lipopolysaccharide targeted either to the airways or
28 the alveoli in man. *PLoS One* 2012;7:e33505.

29